美国

证券和交易委员会

华盛顿特区20549

附表13G/A

根据1934年证券交易法

（修订编号3）*

NEWAMSTERDAM 药品公司 N.V.

（发行人名称）

普通股，每股面值为€0.12

（证券种类名称）

N62509 109

（CUSIP编号）

2024年9月30日

（需要提交此声明的事件的日期）

请选择适用的规定来申明本附表所依据的规则:

¨ 规则 13d-1(b)

x 规则 13d-1(c)

¨ 规则 13d-1(d)

*这份封面的剩余部分将填写关于证券类别的起始申报人初次填写的表格，以及任何随后包含会改变之前封面披露信息的修订。

本封面其余部分需提供的信息不应被视为《证券交易法》第18条规定的“备案”，也不受该法规定的责任限制，但应受该法的所有其他规定约束（但请参阅附注）。

CUSIP编号。 N62509 109

CUSIP编号。 N62509 109

CUSIP编号。 N62509 109

CUSIP编号 N62509 109

NewAmsterdam Pharma公司N.V.（"发行人”)

Gooimeer 2-35, 1411 DC Naarden, 荷兰

提交此报告的人员姓名（以下简称"报告人”）为：

RA Capital Management, L.P.（"RA Capital”) 

Peter Kolchinsky

Rajeev Shah

RA Capital Healthcare Fund, L.P. (the “基金”)

每个报告人的主要营业处所地址均为：

c/o RA Capital Management, L.P., 200 Berkeley 街，18^th 波士顿 MA 02116号楼

RA Capital和基金是特拉华州有限合伙制度。 Kolchinsky博士和Shah先生是美国公民。

普通股份，每股面值为€0.12

N62509 109

无需填写。

The Fund directly holds (i) 8,064,000 Ordinary Shares, (ii) 333,333 warrants (the “Ordinary Share Warrants”) through which it has the right to acquire 333,333 Ordinary Shares and (iii) 2,631,578 pre-funded warrants (the “预先拟定的认股权证。”) through which it has the right to acquire 2,631,578 Ordinary Shares (the “Ordinary Share Warrants” and, together with the Pre-Funded Warrants, the “权证”). Each of the Ordinary Share Warrants and Pre-Funded Warrants contains a provision (the “Beneficial Ownership Blockers”) which precludes exercise of the Warrants to the extent that, following exercise, the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding. The Warrants may be exercised for Ordinary Shares at the election of the holder.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G/A. The beneficial ownership percentages reported are based on (i) 90,015,357 outstanding Ordinary Shares, as reported in the Issuer’s 10-Q filed with the Securities and Exchange Commission on August 7, 2024, plus (ii) 1,031,589 Ordinary Shares which the Reporting Persons may currently acquire upon the exercise of the Warrants.

RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “行动”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the Issuer’s Ordinary Shares reported herein.  Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

如果此声明是为了报告截至本声明日期报告人已不再持有该类证券百分之五以上的受益所有人的事实，请勾选以下选项 ¨.

不适用。

无需填写。

不适用。

不适用。

在下面签名表示，据我所知和相信，上述证券的获取和持有并非出于改变或影响证券发行者控制权的目的或效果，也非出于与具有该目的或效果的交易有关或作为该交易的参与者获取和持有的，除了与§ 240.14a-11项下提名完全相关的活动。

展品清单

附件1: 联合提交协议

签名

经过合理的查询并尽到最大的知识和信任，每个签署人证明本声明中所载信息真实、完整、准确。